Under the leadership of Marie-France Tschudin, President, the Executive Committee of AAA is responsible for overseeing business operations. Each member of the Executive Committee represents a global function.

Executive Committee

Marie-France Tschudin was appointed President of Advanced Accelerator Applications (AAA), a Novartis company, in 2019 and is a member of the Novartis Oncology Leadership team. She has more than 25 years of broad, multi-national experience in the pharmaceutical industry.

Prior to joining AAA, Marie-France was the Head of Region Europe for Novartis Pharmaceuticals, where she led a $7.5 billion business with more than 8,000 associates. During her two-year tenure, she also served as President of the Board for the German, UK, Spanish and Italian affiliates, and was a member of the Pharma Executive Committee.

Before this, Marie-France spent ten years at Celgene International in a variety of leadership positions with increasing responsibility. From 2014 to 2016, she was Corporate Vice President Hematology-Oncology for EMEA and from 2012 to 2014, she held the position of Regional Vice President Northern Europe. From 2010 to 2011, Marie-France was General Manager Central Europe and before that she was General Manager Central Eastern Europe. Her previous roles at Celgene included Country Manager Switzerland / Deputy General Manager smaller Western European countries, and Sales & Marketing Director Western European Region / Interim Country Manager BENELUX.

Marie-France started her career in the pharmaceutical industry as a sales representative at Janssen-Cilag Farmacêutica in Portugal and later managed business units for Essex Chemie AG in Switzerland and Schering-Plough S.A in Spain.

Marie-France is a graduate of Georgetown University, Washington D.C. and holds a Masters in Business Administration from the International Institute for Management Development (IMD), in Lausanne, Switzerland.

Barak Palatchi was appointed Chief Operations Officer of Advanced Accelerator Applications (AAA), a Novartis company, in February of 2019 following his tenure as Chief Commercial Officer in 2018. Barak was Oncology General Manager, UK & Ireland for Novartis from 2016 to February 2018, and a member of the Novartis Oncology Leadership Team, Region Europe. Prior to this, Barak was Oncology General Manager Israel for Novartis from 2012 to June 2016. Before this, he was Head of Marketing for Samsung Israel from 2011 to 2012. Prior to joining Samsung, Barak spent seven years with Pfizer Israel in roles of increasing responsibility including Public Affairs Director, Marketing Director and then Business Unit Director. Barak started his career in the U.S. working as a legislative assistant for New York Congressman Eliot Engel. Barak was a scholar at the Institute for Advance Strategic and Political Studies in Washington D.C., and holds a Bachelor of Arts in Political Science from Bar-Ilan University, Israel.

Germo Gericke, M.D., was appointed Head of Research and Development of Advanced Accelerator Applications (AAA), a Novartis company in 2018. Germo continues his role as a member of the Oncology Development Leadership Team at Novartis. Prior to joining AAA, Germo served as Franchise Global Program Head in the Oncology Global Development Unit of Novartis, where he led cross-functional development activities for compounds in full development and life cycle management. Prior to moving to Oncology Global Drug Development in 2008, Germo served in strategic, commercial and general management roles with increasing responsibility across a range of therapeutic and geographic areas. Germo joined Novartis in 2001 from McKinsey & Company where he was a member of the Global Healthcare Practice. Germo holds a Medical Doctorate from the University of Heidelberg. He studied medicine at Charité University Hospital, Berlin.

Caio Kugelmas is Chief Financial Officer for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA, Caio held positions with various Novartis businesses over the past 12 years. Most recently, he was Vice President and Chief Financial Officer of Navigate Biopharma in San Diego, California, a Novartis-owned business established in 2017, following the Genoptix divestment. Caio has held various senior finance roles at Novartis, including Vice President and Chief Financial Officer of Genoptix; Country and Pharma Chief Financial Officer for Novartis Mexico; and Regional Chief Financial Officer for Novartis Animal Health. Before joining Novartis, Caio worked for Medtronic and GE Healthcare in financial positions of increasing responsibility. Caio holds a Bachelor’s degree in Economics from Universidad Mackenzie in São Paulo, Brazil, and a Master’s in Business Administration from the University of South Carolina in the U.S.

Philippe Dasse is Head of Technical Operations for Advanced Accelerator Applications (AAA), a Novartis company. From 2015 until August 2018, he also held the position of General Manager of AAA France. Philippe joined AAA shortly after the company was founded in 2002, as Responsible Qualified Person. One of his first mandates was to establish pharmaceutical production. Over the past 16 years, he has held multiple roles of increasing responsibility across various functions, including production, regulatory affairs, pharmacovigilance, and quality assurance. Prior to AAA, Philippe worked at Tours Hospital for three years as Hospital Pharmacist and one year in an industrial pharmaceutical company as Quality Assurance Manager. Philippe holds a Doctor of Pharmacy degree from University of Reims, an academic diploma in Radiopharmacy and Quality Assurance from University of Pharmacy Tours, and a Master’s of Science in bio-kinetics of markers from the University of Pharmacy Paris V.

Mujgan Ates, M.D., is Head of Medical Affairs for Advanced Accelerator Applications (AAA), a Novartis company. She has worked in the pharmaceutical industry for over 20 years in both medical and commercial positions, focusing on oncology, hematology and rare diseases. Prior to joining AAA in September 2018, Mujgan worked at Celgene, where she was the Country Medical Director for Turkey since October of 2016. Before this, she spent 10 years with AstraZeneca as Vice President of Medical in Japan, and then as Vice President Medical, International Regions based in the UK. Mujgan also previously held positions at Johnson and Johnson, Janssen, Cilag, and at several domestic pharmaceutical companies in Turkey. Throughout her career, she has driven medical strategy and managed teams in multiple markets including Japan, China, Australia, Brazil, Russia, Latin America, Asia, and the Middle East and Africa for both portfolio and pipeline products. She has also worked closely with global regulatory and health economics teams to support regulatory affairs and market access efforts. Mujgan holds a Medical degree from Gazi University Medical School and studied Pharmacology in Istanbul University Istanbul Medical School.

Katherine Betz-Doherty is Head of Human Resources for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA in 2018, Katherine served as Head of Human Resources for three Novartis Group global functions (Human Resources, Communications & Advocacy and Global Health and Corporate Responsibility). In this position she partnered with leadership teams across the organizational matrix to embed talent, capabilities and a culture agenda. Since joining Novartis in 1999, Katherine has worked on multiple transformational efforts in the areas of acquisitions, innovative business models, and capability development while building people and patient centric cultures. From 2013 to 2016, she was Head of Human Resources for Genoptix, a molecular diagnostics lab and a start-up business acquired by Novartis. Before this she spent several years at Novartis Pharmaceuticals in compensation, talent management, organization development and lastly leading HR Business Partner teams in the Specialty Medicine and Business functions groups for the US General Medicine unit. Katherine started her career in Human Resources working with several well-known global leaders in high tech and consulting, including Dell Computers, Cap Gemini and Anderson Consulting. Katherine holds a Bachelor degree in Labor and Industrial Relations from Pennsylvania State University and a Master degree in Management and Organization Development from College of St. Elizabeth in New Jersey.

Leo Bronfman is Head of Legal and Compliance for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA in September 2018, Leo spent three years at Novartis Oncology, where he was Director, Pharmaceutical Counsel and then Executive Director, Senior Pharmaceutical Counsel where he supported business development and licensing, alliance management and compliance functions. Before Novartis Oncology, Leo held the position of Senior Corporate Counsel for Sandoz U.S., where his responsibilities included legal support for business development and licensing transactions, product-related mergers and acquisitions and technical operations. After graduating from law school and prior to joining Sandoz U.S., Leo practiced law as a mergers and acquisitions corporate associate at various top law firms in New York, where he advised public and private companies on mergers and acquisitions, complex licensing and collaboration transactions, as well as general commercial and finance transactions Leo holds a Juris Doctor degree magna cum laude from Fordham University School of Law, and holds a Bachelor of Science degree magna cum laude from Hunter College, City University of New York.

Jordi Vall-llossera is Head of Quality Assurance for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA in 2018, Jordi served as Global Head of Supply Chain Quality Assurance for Novartis. Before this he was Head of Pharma Supply Chain Quality Assurance and Responsible Person for the Distribution licenses for Novartis Pharma AG and Novartis Pharma Services AG. From 2014 to 2015, Jordi held the position of Global Quality Process Lead for within the Novartis Pharma Quality organization and from 2010 to 2014, he was Global Quality Operations Manager for Products. Jordi first started his tenure at Novartis in 2005, as a Quality IT Manager at a manufacturing site in Spain and moved to Basel in 2009, to oversee the implementation of a Laboratory Information Management System at all Novartis Pharma manufacturing sites. He spent the first five years of his professional career as a Quality Management and Business Consultant specialized in operations and information technology at Accenture (Anderson Consulting) and in private practice. Jordi holds a degree in Technical Agricultural Engineering from the Polytechnic University of Catalonia and a degree in Agronomical Engineering from the University of Lleida, both in Spain. He has also completed a special Quality Management Program at the Escuela Organizacion Industrial in Barcelona, Spain.

Rachel Levine is Head of Communications and Patient Advocacy for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA in 2016, Rachel spent eight years at Cleveland BioLabs, Inc., a publicly traded biotechnology company, as Director of Corporate Development and Communications and then as Vice President of Investor Relations. During her tenure, she led financing activities, investor and media relations, and internal communications, and supported business development and government relations activites. Rachel has specialized in the healthcare sector (including biotechnology, specialty pharmaceuticals, managed care, healthcare services, and medical device and delivery) since 2000. From 2005 to 2007, Rachel served as Managing Director for Grayling, a global integrated communications firm and division of Huntsworth PLC. Before this, she was Managing Director at The Anne McBride Company, a global investor and public relations advisory. Rachel holds a Bachelor’s of Business Administration, with honors from the University of Massachusetts (Amherst, MA).

Thomas Travis was appointed Head of Strategy and Operational Planning of Advanced Accelerator Applications (AAA), a Novartis company in 2018. Prior to joining AAA, Thomas worked as part of Novartis Oncology’s Global Strategy team, where he focused on commercial excellence. Thomas joined Novartis from McKinsey & Company, where he was a member of the Pharmaceuticals and Medical Products Practice from 2013 to 2017. Thomas started his career as a chemical process engineer at Fluor Corporation, an engineering and construction company, before returning to school to study business. Thomas holds a Master of Business Administration, a Master of Engineering Management, and a Bachelor of Chemical Engineering from Northwestern University.